Entero Therapeutics, Inc. products

Capeserod is a selective 5-HT4 receptor partial agonist, which Entero Therapeutics is repurposing and developing for multiple GI conditions. Based on the biological evidence of expression of 5-HT4b receptor subtype in human GI tract, Entero Therapeutics believes that capeserod may directly or indirectly initiate the peristaltic or secretory reflex by releasing neurotransmitters that can decrease colonic transit time and improve bowel movement.

FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). Adrulipase is derived from the Yarrowia lipolytica yeast lipase and is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.

Latiglutenase (IMGX003) is an orally administered mixture of two gluten-specific recombinant proteases that degrades gluten proteins into small physiologically irrelevant fragments, and is to be administered as an adjunct to a gluten-free diet (GFD). As illustrated in the below figure, one protease (IMGX001) is effective at breaking glutamine-leucine bonds and the other protease (IMGX002) targets most proline bonds.

A majority of individuals with CD do not recover well under a GFD. Furthermore, there is still no effective means for monitoring the intestinal health of a recovering celiac other than an invasive biopsy and even that method is prone to interpretive analysis. This problem is particularly acute in the United States where recent studies have shown that more than 50% of adult celiac patients have persistent villous atrophy.

Latiglutenase (IMGX003) is an orally administered mixture of two gluten-specific recombinant proteases that degrades gluten proteins into small physiologically irrelevant fragments that is designed to be administered as an adjunct to a gluten-free diet (GFD).